Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Regulus Therapeutics Inc.

Regulus Therapeutics focuses on developing therapeutics for patients with orphan kidney diseases, particularly targeting the underlying biology of these conditions with microRNA-based therapeutics.

COM:REGULUSRX

Regulus Therapeutics

Last Close

1.40

22/11 21:00

Market Cap

115.22M

Beta: -

Volume Today

288.02K

Avg: -